International Flavors & Fragrances Inc Dossier
|
SectorMaterials IndustrySpecialty Chemicals Beta (adjusted)0.95 Intrinsic Value $53.93median of 6 methods · middle span $16-$81based on filings through 30 Jun 2026 Market Price $83.12Price as of 1 Oct 2026 OvervaluedIntrinsic value is 35% below the market price −50% · IV below pricenear fair value ±15%IV above price · +50% Data confidence Sign in to view data confidence Market Cap $21.2B Enterprise Value $26.3B Shares Outstanding 256M diluted Moat Rating None Next Earnings Date3 Nov 2026 Last ex-dividend18 Sep 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary IFF entered the second half of 2026 with favorable operating momentum: second-quarter comparable currency-neutral sales increased 6%, adjusted operating EBITDA was $408M, and first-half free cash flow reached $378M. The pending Food Ingredients divestiture would concentrate the portfolio in Taste, Scent and Health & Biosciences while supplying approximately $3.8B of net cash proceeds, of which more than $1B is intended for debt reduction. The balance is execution risk: closing is not expected until as late as Q2 2027, about $100M of stranded costs must be removed, and first-half regulatory costs reached $81M. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$76.00 Mean target$95.66 High · most bullish analyst$105.00 Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions. Our research · scenarios, merits, risks, and invalidation triggersResearch as of 2 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $76.0023% Comparable growth falls below guidance, fragrance-market or geopolitical disruption weakens Scent, regulatory costs continue rising, or the Food Ingredients sale is delayed. Slow stranded-cost removal would dilute the expected margin benefit, while delayed proceeds would postpone debt reduction and the remaining repurchase authorization. Base CaseCentral scenario $95.6657% Matches the consensus meanContinuing operations finish 2026 within management's $7.4B-$7.6B sales and $1.53B-$1.60B adjusted operating EBITDA ranges. The Food Ingredients sale closes within the stated Q2 2027 window, most stranded costs are removed over two years, and capital returns proceed while leverage remains controlled. Bull CaseUpside scenario $105.0020% Comparable sales and EBITDA growth remain near or above the upper ends of 2026 guidance, the Food Ingredients transaction closes on schedule, stranded costs are removed as planned, and debt reduction plus the authorized $2.5B repurchase program improve per-share value without pushing leverage above the 2.0x-2.5x objective. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |